The Annexure

News to 9 October 2026 ·

Desk›Healthcare› Anuh Pharma Ltd

Anuh Pharma Ltd

BSE 506260 · NSE ANUHPHR · ISIN INE489G01022 · Group B · Active

Healthcare › Healthcare › Pharmaceuticals & Biotechnology › Pharmaceuticals

₹83.57

+5.92%

BSE close, 28 August 2026

Market cap

₹837.57 cr

10.0 cr shares · Micro cap

Free float

₹233.03 cr

as published

P/E · P/B

18.9× · 2.76×

EPS ₹4.41 · BV ₹30.28

FY25-26 rev / PAT

771.66 / 41.05

₹ cr, as filed

Filings, window

12

4 selected · 33%

Regime

Reg 30

Sch. III Part A

Price 52-week, BSE

52-WK LOW ₹66.72 52-WK HIGH ₹93.00 ₹83.57 64% of range
Against 52-week high-10.1%
Against 52-week low+25.3%
Day change+5.92%
Size bandMicro cap
Index membershipNone

Valuation as published by BSE

Earnings per share₹4.41
Price / earnings18.95×
Price / book2.76×
Book value — derived, price ÷ P/B₹30.28
Return on equity14.57%
Operating margin9.99%
Net margin5.89%

Consistency check

P/B ÷ P/E, which must equal ROE
14.56%
ROE as published
14.57%

Results ₹ crore, as filed

RevenueNet profit one scale across all three periods, ₹ crore

PeriodRevenue ₹cr Net profit ₹cr EPS ₹OPM NPM
Jun-26 · Q 193.81 11.43 1.14 9.99% 5.89%
Mar-26 · Q 202.12 11.68 1.17 9.22% 5.78%
FY25-26 771.66 41.05 4.10 8.56% 5.32%

Quarter on quarter

Revenue, quarter on quarter
-4.1%
Net profit, quarter on quarter
-2.1%
Operating margin, quarter on quarter
+77 bps

Disclosure profile 12 filings in the window

0 median 17.0 p75 · 25 sector max 52 12 29th percentile of 300 Healthcare filers
Shaded is the middle half of the sector, 12 to 25 filings. Measured against the 300 Healthcare companies that filed at all in this window — companies with no filings are excluded, so this is a percentile against filers rather than against the sector.
TagFilings
Selected
Board Outcome1
Change in Management1
Investor Presentation1
Results1
Selected sub-total4
Procedural
General4
AGM / EGM2
Board Meeting1
Trading Window1
Procedural sub-total8
Total12

Disclosure regime

LODR Reg 30

Read with Schedule III Part A. An equity filer in BSE Group B, so the Regulation 30 disclosure framework and the Schedule III event list both apply.

Sources Price, day change, 52-week range — bse.quote, bse.quoteWeeklyHL, 28 August 2026 close. Market cap and free float — bse.getScripTradingStats. P/E, P/B, EPS, ROE, margins — bse.equityMetaInfo. Quarterly and annual results — bse.resultsSnapshot, standalone, as filed. Four-tier classification — data/reference/companies.csv. Filing counts and tags — the build aggregate for this window. Notes Book value is derived as price ÷ P/B; BSE does not publish it directly. Share count is derived as market cap ÷ price. Figures move between captures and between vendors, and the two are not an error in either: companies.csv carries the market cap from an earlier sweep than the snapshot above. EPS appears twice with different meanings — the figure beside P/E is the trailing one from equityMetaInfo, while the EPS in the results table is the per-period figure as filed.

Filing rhythm · 93 trading days

12 filings · 4 selected · busiest 2026-08-07

Filing rhythm · the twelve most recent

2026-08-032026-09-28

SelectedProcedural

Filings

12 in the window · 4 earlier on record

  1. 28 September 2026 ·

    Trading Window

    Closure of Trading Window

    Intimation regarding the closure of Trading Window for dealing in Securities of the Company shall remain closed from Thursday, 01st October, 2026 till the expiry of 48 hours after the declaration ....

    Insider Trading / SAST / Closure of Trading Window View filing →

  2. 18 September 2026 ·

    General

    Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 ('SEBI LODR')

    Disclosure under Regulation 30 of the SEBI LODR regarding receipt of Demand Order under Section 156 of the Inc ome Tax Act, 1961.

    Company Update / General View filing →

  3. 19 August 2026 ·

    Investor Presentation

    Investor Presentation

    Investor Presentation for Q1 FY 2026-27

    Company Update / Investor Presentation View filing →

  4. 14 August 2026 ·

    Change in Management

    Change in Management

    Disclosure under Regulation 30 of SEBI (LODR), 2015 regarding Change in Management.

    Company Update / Change in Management View filing →

  5. 14 August 2026 ·

    General

    Announcement Under Regulation 30 - General Updates

    Disclosure of Announcement under Regulation 30 of SEBI (LODR), 2015

    Company Update / General View filing →

  6. 14 August 2026 ·

    AGM / EGM

    Shareholder Meeting / Postal Ballot-Scrutinizer's Report

    Submission of Scrutinizer Report and Voting Results for the 66th Annual General Meeting of the Company

    AGM/EGM / AGM View filing →

  7. 12 August 2026 ·

    AGM / EGM

    Shareholder Meeting / Postal Ballot-Outcome of AGM

    Outcome of the 66th Annual General Meeting of Anuh Pharma Limited held on Wednesday, 12th August, 2026

    AGM/EGM / AGM View filing →

  8. 7 August 2026 ·

    General

    Adoption Of Revised Policy Of Related Party Transactions,

    Adoption of Revised Policy of Related Party Transactions.

    Company Update / General View filing →

  9. 7 August 2026 ·

    General

    Intimation Regarding The Request Received For Withdrawal Of Application For Reclassification.

    Request received for Withdrawal of application for reclassification of shareholding from "Promoter & Promoter Group' to 'Public Category'.

    Company Update / General View filing →

  10. 7 August 2026 ·

    Results

    Results - Financial Results For June 30, 2026

    Unaudited Financial Results for the Quarter ended 30th June, 2026.

    Result / Financial Results View filing →

  11. 7 August 2026 ·

    Board Outcome

    Board Meeting Outcome for Board Meeting Outcome For The Board Meeting Held On 07/08/2026

    To consider and approve the Unaudited Financial results along with the Limited Review Report for the quarter ended 30th June, 2026, Request received for withdrawal of application for reclassification ....

    Board Meeting / Outcome of Board Meeting View filing →

  12. 3 August 2026 ·

    Board Meeting

    Board Meeting Intimation for Consideration And Approval Of Unaudited Financial Results For The Quarter Ended 30Th June, 2026.

    Anuh Pharma Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/08/2026 ,inter alia, to consider and approve Unaudited Financial Results for ....

    Board Meeting / Board Meeting View filing →

RSS feed for Anuh Pharma Ltd · the 50 most recent filings